abs344.txt	purpose		after	failure	of	hypomethylating	agents	(hma)	patients	withmyelodysplastic	syndromes	(mds)	have	dismal	survival	and	no	approved	treatmentoptions	methods	we	conducted	a	phase	1b	investigator-initiatedtrial	ipilimumab	in	with	higher	risk	mds	who	failed	hmas	received	monotherapy	at	two	dose	levels	(dl	3	10	mg/kg)	aninduction	followed	by	maintenance	toxicities	responses	wereevaluated	ctcae	4	iwg-2006	criteria	respectively	also	performedimmunologic	assays	t-cell	receptor	sequencing	on	serial	samples	results	twenty-nine	from	7	centers	were	enrolled	the	initial	dl1	(3	mg)	3of	6	experienced	grade	2-4	immune-related	adverse	events	(irae)	thatwere	reversible	drug	discontinuation	and/or	systemic	steroids	dl2	of5	2	or	irae	thus	was	expandedwith	iraes	reported	18	additional	best	responsesincluded	marrow	complete	response	(mcr)	one	patient	4%)	prolonged	stabledisease	(psd)	for	≥46	weeks	occurred	(24%	entire	cohort	29%of	those	treated	mg/kg	dose)	including	more	than	yearof	sd	five	underwent	allografting	without	excessive	toxicity	mediansurvival	group	294	days	(95%	ci	240-671+)	achieved	psdor	mcr	had	significantly	frequency	t	cells	expressing	icos	(induciblet-cell	co-stimulator)	conclusions	our	findings	suggest	that	dosed	at3	hma	is	safe	but	has	limited	efficacyas	increased	icos-expressing	might	predictclinical	benefit	clin	cancer	res	24(15)	3519-27	©2018	aacr
